The PD-L1 expression was an established biomarker for anti-PD-1/PD-L1 monotherapy in NSCLC and remains a suitable biomarker to predict the PFS benefit with ICI+chemo versus beva +chemo in this study. Here, CD274 is linked to non-small cell lung carcinoma.